|
ATP5J expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.51979999996055E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.74638999999033E-05 |
| Normal-vs-Stage2 |
8.656800E-01 |
| Normal-vs-Stage3 |
2.30000000156494E-08 |
| Normal-vs-Stage4 |
2.8643976079934E-11 |
| Stage1-vs-Stage2 |
1.579810E-02 |
| Stage1-vs-Stage3 |
7.909800E-02 |
| Stage1-vs-Stage4 |
5.95420000000235E-05 |
| Stage2-vs-Stage3 |
2.040200E-03 |
| Stage2-vs-Stage4 |
5.57629999999865E-05 |
| Stage3-vs-Stage4 |
2.204100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.85820000287285E-08 |
| Normal-vs-AfricanAmerican |
2.003700E-02 |
| Normal-vs-Asian |
1.86559999999503E-05 |
| Caucasian-vs-AfricanAmerican |
2.635400E-01 |
| Caucasian-vs-Asian |
9.737200E-01 |
| AfricanAmerican-vs-Asian |
3.139000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.336290E-03 |
| Normal-vs-Female |
1.09859999997131E-06 |
| Male-vs-Female |
2.393800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.61979999999873E-05 |
| Normal-vs-Age(41-60Yrs) |
4.30519999983225E-07 |
| Normal-vs-Age(61-80Yrs) |
1.066380E-02 |
| Normal-vs-Age(81-100Yrs) |
3.50500000000364E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.475800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.839600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.811700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.100100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.665400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.369900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.677090E-03 |
| Classical-VS-Follicular |
5.26879651019385E-11 |
| Classical-VS-Other |
5.585200E-01 |
| Classical-VS-Normal |
7.46199768641986E-11 |
| Tall-VS-Follicular |
1.65145674912992E-12 |
| Tall-VS-Other |
2.499600E-01 |
| Tall-VS-Normal |
2.38453701228991E-12 |
| Follicular-VS-Other |
1.251360E-01 |
| Follicular-VS-Normal |
2.615800E-01 |
| Other-VS-Normal |
2.780000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.835300E-03 |
| Normal-vs-N1 |
6.07049965850592E-11 |
| N0-vs-N1 |
3.00139999964699E-07 |
|
|
